Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2831-2839

  Leighl, Natasha B ^a   Paz Ares, Luis ^a   Douillard, Jean Yves ^a   Peschel, Christian ^a   Arnold, Andrew ^a   Depierre, Alain ^a   Santoro, Armando ^a   Betticher, Daniel C ^a   Gatzemeier, Ulrich ^a   Jassem, Jacek ^a   Crawford, Jeffrey ^a   Tu, Dongsheng ^a   Bezjak, Andrea ^a   Humphrey, Jeffrey S ^a   Voi, Maurizio ^a   Galbraith, Susan ^a   Hann, Katherine ^a   Seymour, Lesley ^a   Shepherd, Frances A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; REBIMASTAT; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MATRIX METALLOPROTEINASE; N ((2S) 2 MERCAPTO 1 OXO 4 (3,4,4 TRIMETHYL 2,5 DIOXO 1 IMIDAZOLIDINYL)BUTYL) L LEUCYL N,3 DIMETHYL L VALINAMIDE; N-((2S)-2-MERCAPTO-1-OXO-4-(3,4,4- TRIMETHYL-2,5-DIOXO-1-IMIDAZOLIDINYL)BUTYL)-L-LEUCYL-N,3- DIMETHYL-L-VALINAMIDE; ORGANIC COMPOUND; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANADA; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; ORGANIC CHEMICALS; PACLITAXEL; PLACEBOS; TREATMENT OUTCOME;

EID: 21044453902     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.044     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, et al: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156, 2001
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy for non-small cell lung cancer [Cochrane Database System Review]. Oxford, England, Cochrane Library, CD002139, issue 2, 2000
3. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
4. Shepherd FA, Pereira J, Ciuleanu T, et al: A randomized placebo-controlled study of erlotinib (OSI-774, Tarceva) versus placebo in patients with incurable non-small cell lung cancer who have failed standard therapy for advanced or metastatic disease. Proc Am Soc Clin Oncol 22:6225, 2004 (abstr 7022)
5. Janecki-Delebecq T, Porte H, Zerimech F, et al: Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res 6:1086-1092, 2000
6. Passlick B, Srenel W, Seen-Hibler R, et al: Overexpression of matrix metalloproteinases predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 6:3944-3948, 2000
7. Brown PD, Bloxidge RE, Stuart NS, et al: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574-578, 1993
8. Garbisa S, Scagliotti G, Masiero L, et al: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52:4548-4549, 1992
9. Thomas P, Khokha R, Shepherd FA, et al: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190:150-156, 2000
10. Simi L, Andreani M, Davini F, et al: Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer 45:171-179, 2004
11. Aljada IS, Ramnath N, Donohue K, et al: Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein is associated with progression of human non-small cell lung cancer. J Clin Oncol 22:3218-3229, 2004
12. Shepherd FA, Sridhar SS: Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41:563-572, 2003 (suppl 1)
13. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002
14. Bissett D, O'Byrne K, von Pawel J, et al: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 21:296a, 2002 (abstr 1183)
15. Douillard JY, Peschel C, Shepherd F, et al: Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 46:361-368, 2004
16. Bristol-Myers Squibb Pharmaceutical Research Institute: Investigator Brochure-Matrix metalloproteinase inhibitor BMS-275291, version 4. Bristol-Myers Squibb, Wallingford, CT, 2002
17. Lombard MA, Wallace TL, Kubicek MF, et al: Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 58:4001-4007, 1998
18. Rizvi NA, Humphrey JS, Ness EA, et al: A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 10:1963-1970, 2004
19. Douillard JY, Peschel C, Shepherd F, et al: Randomized phase II study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 46:361-368, 2004
20. Tu D: Minimization Procedure, in Chow SC (ed) Encyclopaedia of Biopharmaceutical Statistics. New York: Marcel Dekker, Inc. 2003, pp 614-618
21. Miller KD, Saphner TJ, Waerhouse DM, et al: A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10:1971-1975, 2004
22. Lara PN, Longmate J, Stadler W, et al: Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. Proc Am Soc Clin Oncol 23:417, 2004 (abstr 4647)